- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Diatide partner Angstrom wins cancer patent
Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies’ efforts to develop anticancer therapeutic
Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies efforts to develop anticancer therapeutic products.
In March, Diatide and Angstrom created a license agreement that gives Diatide exclusive rights to tumor imaging and anticancer therapeutics based on Angstroms uPAR (urokinase plasminogen activator receptor) targeting technology. The agreement stipulates that Diatide will pay Angstrom research and milestone payments, as well as royalties on product sales (SCAN 4/28/99). The firms are working together on research that combines Diatides peptide analog development expertise with Angstroms knowledge of uPAR-binding peptides.
UPAR is found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth. Angstroms latest patent covers a broad class of cyclic peptides that bind to uPAR.
In other Diatide news, the Londonderry, NH, companys NeoTect lung tumor agent has begun shipping. NeoTect received Food and Drug Administration clearance last month (SCAN 8/18/99). Diatide has a marketing partnership with Nycomed Amersham, although the Buckinghamshire, U.K., firm sold its share in the U.S. company in June (SCAN 6/23/99).
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.
